Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...

The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional ...

We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this ...

Sacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences ...

On October 8, 2024, PhRMA held a media briefing to address growing concerns over the Inflation Reduction Act (IRA) and its effects on the biopharmaceutical industry, Medicare Part D beneficiaries, and ...

Jefferies analyst Michael Yee maintained a Hold rating on Moderna (MRNA – Research Report) today and set a price target of $55.00. The ...

Oncology is forecast to be the biggest revenue-generating segment ... Some of the key players in the cell and gene therapy ...

California-based Gilead had already announced its strong intentions in oncology in 2017 with its $11.9 billion purchase of Kite Pharma, followed by the acquisition of immuno-oncology firm Forty ...

Gilead pounced to buy cell therapy company Kite ... two leading platforms to develop best-in-class cell therapies in oncology," said Sandy Macrae, president and chief executive officer of Sangamo.

Jefferies analyst Michael Yee maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $380.00. The ...